Brief: Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, Cd40 Agonist Antibody, At Asco Gastrointestinal Cancers Symposium 2023
19/01/2023 13:07
Jan 19 (Reuters) - Apexigen Inc APGN.O :
* APEXIGEN ANNOUNCES NEW PHASE 2 DATA EVALUATING
SOTIGALIMAB, ITS
CD40 AGONIST ANTIBODY, AT ASCO GASTROINTESTINAL CANCERS
SYMPOSIUM 2023
Source text for Eikon: ID:nGNX5H38BG
Further company coverage: APGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq